IP Library Granted Patent US 12,274,729
Granted Patent B2
US 12,274,729 · App. 18/764,024 · Granted Apr 15, 2025

Formulations and methods for skin care or hyaluronic acid synthesis

Inventors: Apostolos Pappas (Norwood, MA); Olga Ilnytska (Norwood, MA)
Assignee: AMILYFE, LLC
A61K36/324A61K8/44A61K8/442A61K8/492A61K8/671A61K8/9789A61K9/00A61K31/07A61K31/11A61K31/198A61K31/203A61K31/232A61K31/405A61K36/32A61K45/06A61K47/24A61K47/38A61Q19/00A61K2800/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,274,729
App. No.
18/764,024
Granted
Apr 15, 2025
Kind
B2
Abstract

Cosmetic and pharmaceutical formulations comprising specific amino acid combinations are described herein. Such formulations strengthen and enhance skin epithelial cell barrier function, thereby reducing moisture loss from the skin and restoring skin's structural integrity, epithelial differentiation, intercellular adhesion, and intracellular signaling and/or promoting maintenance of these features. Formulations described here comprise a therapeutically effective amount of free amino acids or a peptide combination of amino acids and either a therapeutically effective amount of a plant extract for skin barrier repair or a therapeutically effective amount of a retinoid for improving skin moisture. Also provided are injectable formulations described here for treating a subject suffering from osteoarthritis or symptoms thereof. Methods for administering these formulations for cosmetic and/or therapeutic purposes and uses thereof for same are also described herein, including the use thereof in the preparation of medicaments.

Claims (34)

1. A topical formulation, comprising:

(a) as free amino acids or a peptide combination of amino acids, a therapeutically effective amount of a combination consisting of:

alanine, glutamine, glycine, and serine, or salts thereof,

wherein each free amino acid has a ratio to each of the other free amino acids of 1:100 or greater; and

(b) a therapeutically effective amount of a retinoid,

wherein the therapeutically effective amount of the combination and the therapeutically effective amount of the retinoid improve skin moisture when tested by a method detecting expression of epidermal growth factor (EGF) or hyaluronic acid (HA) marker gene and determining that the EGF marker gene expression or the HA marker gene expression is upregulated by 1.4 fold-450 fold for formulation treated skin cells as compared to untreated skin cells,

wherein the therapeutically effective amount of the combination and the therapeutically effective amount of the retinoid improves skin moisture; and

wherein the only amino acids present in the topical formulation are alanine, glutamine, glycine, and serine, or salts thereof.

2. The topical formulation according to claim 1 , wherein each of the amino acids is present at a concentration of: 0.1 mM or greater; 10 mM or less; or 0.1 mM to 10 mM.

3. The formulation according to claim 1 , wherein each of the amino acids is present at a weight percent to the formulation (wt/wt %) of 0.001 wt % or greater; 1 wt % or less; or 0.001 wt % to 1 wt %.

4. The topical formulation according to claim 1 , wherein the therapeutically effective amount of the retinoid is present at a weight percentage (w/w %) of the formulation of 0.01 w/w % or greater; 5 w/w % or less; or 0.01 w/w %-5 w/w %.

5. The topical formulation according to claim 1 , wherein the retinoid is selected from the group consisting of: retinyl; retinol or vitamin A; retinaldehyde or retinal; retinoic acid; or combinations thereof.

6. The topical formulation according to claim 1 , wherein the therapeutically effective amount of the combination of (a) and the therapeutically effective amount of the retinoid of (b) increase skin moisture, decrease loss of moisture, increase hyaluronic acid (HA), increase hyaluronic acid synthase (HAS), or combinations thereof.

7. The topical formulation according to claim 6 , wherein increasing HAS comprises increasing: HAS1 in fibroblasts, increasing HAS2 and/or HAS3 in keratinocytes, or combinations thereof.

8. The topical formulation according to claim 1 , further comprising:

a texturing and/or a bulking agent;

a phospholipid;

an anti-caking agent;

a dermatologically acceptable vehicle and/or additive; or

combinations thereof.

9. The topical formulation of claim 8 , wherein the bulking agent comprises cellulose, microcrystalline cellulose, or combinations thereof.

10. The topical formulation of claim 8 , wherein the phospholipid comprises lecithin, phosphatidylcholine, or combinations thereof.

11. The topical formulation of claim 8 , wherein the anti-caking agent comprises silica.

12. The topical formulation of claim 8 , wherein the additives are selected from the group consisting of: vitamins, minerals, preservatives, desquamation agents, anti-acne agents, anti-wrinkle agents/anti-atrophy agents, hydroxyl acids, anti-oxidants/radical scavengers, chelators, flavonoids, anti-inflammatory agents, anti-cellulite agents, topical anesthetics, tanning agents, skin lightening agents, skin soothing and skin healing agents, antimicrobial and antifungal agents, sunscreen agents, conditioning agents, structuring agents, thickening agent, and preservatives, or any combinations thereof.

13. The topical formulation according to claim 1 , wherein at least one amino acid is in L-form.

14. A method, comprising:

administering the topical formulation according to claim 1 to skin a subject suffering from a skin condition,

wherein, the method:

improves skin moisture;

increases HAS1 expression in fibroblasts;

increases HAS2 expression and/or HAS3 expression in keratinocytes; or combinations thereof.

15. The method according to claim 14 ,

wherein administering the topical formulation improves at least one visual property, or at least one tactile property, or a combination of visual and tactile properties of the skin,

wherein the skin condition comprises a cosmetic skin condition, atopic dermatitis, dermatitis, psoriasis, pruritus, eczema, a wound, or a burn.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2025
From: PAPPAS, APOSTOLOS; ILNYTSKA, OLGA
To: AMILYFE, LLC
Reel/Frame 069767/0128 →
CHANGE OF NAME Recorded Jan 6, 2025
From: ENTRINSIC, LLC
To: AMILYFE, LLC
Reel/Frame 069826/0751 →
CHANGE OF NAME Recorded Jan 2, 2025
From: ENTRINSIC, LLC
To: AMILYFE, LLC
Reel/Frame 069808/0900 →
Continuity (3)
Continuation PCTUS2023017246 · Apr 3, 2023
Continuation In Part PCTUS2022082663 · Dec 30, 2022
Related Publication 20240350388A1 · Oct 24, 2024
References Cited (16)
US 5859208A · Fiddes et al. · 1999 [cited by applicant]
US 6149924A · Paul · 2000 [cited by examiner]
US 20070092461A1 · Gupta · 2007 [cited by applicant]
US 20080050346A1 · Jimenez et al. · 2008 [cited by applicant]
US 20100247563A1 · Hines et al. · 2010 [cited by applicant]
US 20110183040A1 · Ermolin et al. · 2011 [cited by applicant]
US 20110201578A1 · Maniga · 2011 [cited by examiner]
US 20120225029A1 · Al-Qahtani · 2012 [cited by applicant]
US 20130108603A1 · Bennett · 2013 [cited by examiner]
US 20150150974A1 · Duprat · 2015 [cited by examiner]
US 20150299311A1 · Reversade · 2015 [cited by applicant]
US 20210283081A1 · Vidyasagar et al. · 2021 [cited by applicant]
US 20230233433A1 · Stewart · 2023 [cited by examiner]
Maeno, “Direct Quantification of Natural Moisturizing Factors in Stratum Corneum using Direct Analysis in Real Time Mass Spectrometry with Inkjet-Printing Technique,” Scientic Reports (2019) 9:17789. (Year: 2019). [cited by examiner]
International Search Report and Written Opinion dated Jun. 14, 2023 for PCT/US2022/082663. [cited by applicant]
International Search Report and Written Opinion dated Aug. 24, 2023 for PCT/US2023/017246. [cited by applicant]